S
Shlomit Yust-Katz
Researcher at Rabin Medical Center
Publications - 69
Citations - 2458
Shlomit Yust-Katz is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 20, co-authored 62 publications receiving 1411 citations. Previous affiliations of Shlomit Yust-Katz include Fujita Health University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah Nejman,Ilana Livyatan,Garold Fuks,Nancy Gavert,Yaara Zwang,Leore T. Geller,Aviva Rotter-Maskowitz,Roi Weiser,Roi Weiser,Giuseppe Mallel,Elinor Gigi,Arnon Meltser,Gavin M. Douglas,Iris Kamer,Vancheswaran Gopalakrishnan,Tali Dadosh,Smadar Levin-Zaidman,Sofia Avnet,Tehila Atlan,Zachary A. Cooper,Reetakshi Arora,Alexandria P. Cogdill,Abdul Wadud Khan,Gabriel Ologun,Yuval Bussi,Adina Weinberger,Maya Lotan-Pompan,Ofra Golani,Gili Perry,Merav Rokah,Keren Bahar-Shany,Elisa A. Rozeman,Christian U. Blank,Anat Ronai,Ron Shaoul,Amnon Amit,Amnon Amit,Tatiana Dorfman,Ran Kremer,Zvi R. Cohen,Zvi R. Cohen,Sagi Harnof,Sagi Harnof,Tali Siegal,Einav Yehuda-Shnaidman,Einav Nili Gal-Yam,Hagit Shapira,Nicola Baldini,Morgan G. I. Langille,Alon Ben-Nun,Alon Ben-Nun,Bella Kaufman,Bella Kaufman,Aviram Nissan,Talia Golan,Talia Golan,Maya Dadiani,Keren Levanon,Keren Levanon,Jair Bar,Jair Bar,Shlomit Yust-Katz,Shlomit Yust-Katz,Iris Barshack,Iris Barshack,Daniel S. Peeper,Dan J. Raz,Eran Segal,Jennifer A. Wargo,Judith Sandbank,Noam Shental,Ravid Straussman +71 more
TL;DR: A comprehensive analysis of the tumor microbiome was undertaken, studying 1526 tumors and their adjacent normal tissues across seven cancer types, finding that each tumor type has a distinct microbiome composition and that breast cancer has a particularly rich and diverse microbiome.
Journal ArticleDOI
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Amir Massarweh,Noa Eliakim-Raz,Noa Eliakim-Raz,Amos Stemmer,Adva Levy-Barda,Shlomit Yust-Katz,Shlomit Yust-Katz,Alona Zer,Alona Zer,Alexandra Benouaich-Amiel,Haim Ben-Zvi,Haim Ben-Zvi,Neta Moskovits,Baruch Brenner,Baruch Brenner,Jihad Bishara,Jihad Bishara,Dafna Yahav,Dafna Yahav,Boaz Tadmor,Tal Zaks,Salomon M. Stemmer,Salomon M. Stemmer +22 more
TL;DR: In this paper, the authors evaluated rates of antispike (anti-S) antibody response to a BNT162b2 vaccine in patients with cancer who are undergoing systemic treatment vs healthy controls.
Journal ArticleDOI
Neurologic complications of immune checkpoint inhibitors
Avi Fellner,Chen Makranz,Michal Lotem,Felix Bokstein,Felix Bokstein,Alisa Taliansky,Shai Rosenberg,Deborah T. Blumenthal,Deborah T. Blumenthal,Jacob Mandel,Suzana Fichman,Suzana Fichman,Elena Kogan,Israel Steiner,Tali Siegal,Alexander Lossos,Shlomit Yust-Katz,Shlomit Yust-Katz +17 more
TL;DR: This series highlights the very broad spectrum of neurological complications of ICPIs, emphasizes the need for expedited diagnosis and suggests that withholding treatment early, accompanied with steroid therapy, carries the potential of complete resolution of the neurological immune-mediated condition.
Journal ArticleDOI
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Elizabeth Dudnik,Shlomit Yust-Katz,Hovav Nechushtan,Daniel A. Goldstein,Alona Zer,Dov Flex,Tali Siegal,Tali Siegal,Nir Peled,Nir Peled +9 more
TL;DR: Nivolumab might have intracranial activity and favorable safety profile in patients with CNS metastases secondary to NSCLC, and CNS activity warrants further evaluation.
Journal ArticleDOI
The effect of duloxetine on primary pain symptoms in Parkinson disease.
TL;DR: Duloxetine seems to be effective for the treatment of central pain in PD, with varying degrees of pain relief.